| 2.25 -0.15 (-6.25%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.54 | 1-year : | 4.19 |
| Resists | First : | 3.03 | Second : | 3.58 |
| Pivot price | 2.8  |
|||
| Supports | First : | 2.13 | Second : | 1.77 |
| MAs | MA(5) : | 2.35 |
MA(20) : | 2.8 |
| MA(100) : | 2.49 |
MA(250) : | 3.48 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 14.4 |
| RSI | RSI(14): 35.6 |
|||
| 52-week | High : | 5.9 | Low : | 1.79 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GENE ] has closed above bottom band by 11.3%. Bollinger Bands are 82.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.46 - 2.47 | 2.47 - 2.49 |
| Low: | 2.1 - 2.11 | 2.11 - 2.13 |
| Close: | 2.23 - 2.25 | 2.25 - 2.27 |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Wed, 24 Apr 2024
Genetic Technologies raises US$2 million as it eyes global expansion - Proactive Investors Australia
Tue, 23 Apr 2024
Genetic Technologies Secures $2M in Direct Offering - TipRanks.com - TipRanks
Mon, 22 Apr 2024
Genetic Technologies closes US$2 million Registered Direct Offering - Proactive Investors USA
Mon, 22 Apr 2024
Genetic Technologies Announces Closing of US$2 Million - GlobeNewswire
Mon, 22 Apr 2024
Genetic Technologies Launches U.S. Capital Raise - TipRanks.com - TipRanks
Thu, 18 Apr 2024
Genetic Technologies launches US$2 million share offering to fund expansion and innovation - Proactive Investors USA
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 4 (M) |
| Shares Float | 102 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 60 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | -124.1 % |
| Operating Margin | -106 % |
| Return on Assets (ttm) | -52.8 % |
| Return on Equity (ttm) | -160.5 % |
| Qtrly Rev. Growth | -2.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.65 |
| EBITDA (p.s.) | -2.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -15 |
| PEG Ratio | 0 |
| Price to Book value | 56.25 |
| Price to Sales | 0.84 |
| Price to Cash Flow | -1.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|